1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Mystic Miss Not Make Or Break For Imfinzi

 
• By Kevin Grogan

While the failure of AstraZeneca's Imfinzi in the MYSTIC trial for stage IV lung cancer is a blow, it is not going to have much of an effect on the potential for the company which has carved out a sizeable niche for the drug in stage III NSCLC.

Fortune
Mystic message not good news for AstraZeneca • Source: Shutterstock

AstraZeneca PLC' s confirmation that the closely-watched MYSTIC lung cancer trial of Imfinzi (durvalumab) has failed has disappointed investors but the company is keeping faith with the PD-L1 inhibitor and tremelimumab in other NSCLC trials.

Hopes have not been high for MYSTIC since the initial release of data back in July 2017 which showed that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 
• By Alaric DeArment

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

More from R&D

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.